Expanding Theranostic Radiopharmaceuticals for Tumor Diagnosis and Therapy.
Griessinger, Christoph M
Windhorst, Albert D
Jacobs, Andreas H
MetadataShow full item record
Barca, C., Griessinger, C. M., Faust, A., Depke, D., Essler, M., Windhorst, A. D., Devoogdt, N., et al. (2021). Expanding Theranostic Radiopharmaceuticals for Tumor Diagnosis and Therapy.. Pharmaceuticals (Basel) https://doi.org/10.3390/ph15010013
Radioligand theranostics (RT) in oncology use cancer-type specific biomarkers and molecular imaging (MI), including positron emission tomography (PET), single-photon emission computed tomography (SPECT) and planar scintigraphy, for patient diagnosis, therapy, and personalized management. While the definition of theranostics was initially restricted to a single compound allowing visualization and therapy simultaneously, the concept has been widened with the development of theranostic pairs and the combination of nuclear medicine with different types of cancer therapies. Here, we review the clinical applications of different theranostic radiopharmaceuticals in managing different tumor types (differentiated thyroid, neuroendocrine prostate, and breast cancer) that support the combination of innovative oncological therapies such as gene and cell-based therapies with RT.
Gene therapy, Tumor, Positron emission tomography, Radiopharmaceuticals, Molecular Imaging, Theranostics, Cell-based Therapy
European Commission Horizon 2020 (H2020) Societal Challenges (831514)
External DOI: https://doi.org/10.3390/ph15010013
This record's URL: https://www.repository.cam.ac.uk/handle/1810/334310
Attribution 4.0 International
Licence URL: https://creativecommons.org/licenses/by/4.0/